Comments to FDA: Remote Regulatory Assessments Draft Guidance Share page: Docket Number: FDA-2022-D-0810 CHPA appreciates the opportunity to provide comments on FDA Remote Regulatory Assessments Draft Guidance. Download Document Issues: OTC Medicines Dietary Supplements Consumer Medical Devices Related Posts CHPA Impacts Spring 2023 May 17, 2023 Comments Comments Regarding CSPI Synthetic Dye Petition May 12, 2023 Press Releases and Statements CHPA Applauds FDA Advisory Panel’s Unanimous Recommendation to Approve First-Ever OTC Daily Oral Contraceptive May 10, 2023